different indications for their science are there. unfortunately, ariad is still a small player in the field, with financial limitation. being able to move those indications forward, without diluting the share price any further, is a concerning obstacle. I'm sure the higher ups are aware of that financial burden. logic should prevail.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.